Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab

Bone Marrow Transplantation

Volumn 48, Issue 11, 2013, Pages 1465-1471

  Van Der Velden, W J F M ^a   Mori, T ^a,b   Stevens, W B C ^a   De Haan, A F J ^a   Stelma, F F ^a   Blijlevens, N M A ^a   Donnelly, J P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IDARUBICIN; RITUXIMAB; THYMOCYTE ANTIBODY; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EPSTEIN BARR VIRUS INFECTION; FEASIBILITY STUDY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE; T CELL DEPLETION; VIRUS LOAD;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84887217610     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.84     Document Type: Article

References (0)